Fig. 3

Significant causal associations identified for GVHD and relapse risk. A The forest plot shows the OR values and CIs of pyridoxate on aGVHD₃ FS risk estimated using different MR methods; B scatterplot of causal association between pyridoxate and aGVHD₃ FS risk; C funnel plot of causal associations between pyridoxate and aGVHD₃ FS risk; D the forest plot shows the OR values and CIs of glycochenodeoxycholate on aGVHD₃ URD risk estimated using different MR methods; E scatterplot of causal association between glycochenodeoxycholate and aGVHD₃ URD risk; F funnel plot of causal associations between glycochenodeoxycholate and aGVHD₃ URD risk; G the forest plot shows the OR values and CIs of 1-stearoylglycerophosphoethanolamine on aGVHD₃ URD risk estimated using different MR methods; H scatterplot of causal association between 1-stearoylglycerophosphoethanolamine and aGVHD₃ URD risk; I funnel plot of causal associations between 1-stearoylglycerophosphoethanolamine and aGVHD₃ URD risk; J the forest plot shows the OR values and CIs of proline on relapse ALL risk estimated using different MR methods; K scatterplot of causal association between proline and relapse ALL risk; L funnel plot of causal associations between proline and relapse ALL risk. Abbreviation: GVHD, graft-versus-host disease; FS, matched siblings; URD: matched unrelated donor